Gam1983/iStock via Getty Images
Eli Lilly (NYSE:LLY) is the weight loss drug stock with the most potential for upside, according to Seeking Alpha’s July Sentiment Survey.
July’s Sentiment Survey by Seeking Alpha is out, covering what’s hot in the markets, the economy and other current themes.
According to the survey, a majority of investor respondents (40.2% of 823 responses) see Eli Lilly (LLY) as the weight loss drug company with the most upside.
Novo Nordisk (NVO) ranked right under, receiving 30.7% of the vote, with 253 respondents saying it was the weight loss drug stock with the most upside potential.
Then, 8.9% of investors respondents (73 of them) said it was Amgen (AMGN), followed by 7.2% of them (or 59 respondents) naming AstraZeneca (AZN) as the weight loss drug stock with the most upside, and after that Viking Therapeutics (VKTX), with 6.2% or 51 respondents.
Other weight loss drug stocks mentioned, getting under 2% of the vote, included Altimmune (ALT), Pfizer (PFE), AbbVie (ABBV), Zealand Pharma (OTCPK:ZLDPF), Corbus Pharmaceuticals (CRBP), Ventyx Biosciences (VTYX), and Structure Therapeutics (GPCR).
Here is last month’s survey.